Results reported herein are from analysis of approximately 50,200 baseline surveys. Patients were categorized as high risk for fracture based on a fracture index score of less than or equal to 5, according to Black et al(v). Bone medications included bishosphonates, raloxifene, strontium ranelate, parathyroid hormone (1-84), teriparatide, tibolone, and calcitonin.
GLOW is being conducted by The Center for Outcomes Research (COR), University of Massachusetts Medical School (UMMS), with the support of an unrestricted research grant from The Alliance for Better Bone Health. The Alliance for Better Bone Health is a collaboration between sanofi-aventis and Procter & Gamble Pharmaceuticals.
Available for comment:
Dr. Robert Lindsay
Executive committee co-chair, GLOW, Professor of Clinical Medicine, Columbia University and Chief of Internal Medicine at Helen Hayes Hospital, West Haverstraw, NY, USA
(i) Osteoporosis in the European Community: A call to action. Report by the International Osteoporosis Foundation. (c) Copyright 1999-2007 IOF. Accessed 06.02.08, available from http://www.iofbonehealth.org/publications/eu-policy-report-of-2001.html
(ii) Keene GS, Parker MJ and Pryor GA. Mortality and morbidity after hip fractures. BMJ. 1993 (6914):307;1248-50
(iii) Kanis JA and Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis Int. 2005:16; 229-38
(iv) Kanis JA, Delmas P, Burckhardt P, Cooper C and Torgerson D.
Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int.
|SOURCE University of Massachusetts Medical School|
Copyright©2008 PR Newswire.
All rights reserved